Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03418532 · ClinicalTrials.gov registry record · Phase 1
MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC
A Phase 1 study, sponsored by Molecular Partners.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT03418532 is a Phase 1 study that was terminated before completion, run by Molecular Partners. The registered enrollment target is 8 participants.
The verdict
NCT03418532, a Phase 1 study, was terminated before completion, sponsored by Molecular Partners.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the anti-tumor efficacy, safety, tolerability, pharmacokinetics (PK), immunogenicity and biological activity of the MP0250 DARPin® drug candidate in combination with osimertinib orally once daily (o.d.), when administered to patients with EGFR mutated, advanced, non squamous NSCLC after tumor progression on osimertinib and on or after the most recent therapy. MP0250 is a multi-DARPin® protein with three specificities, able to simultaneously neutralize the activities of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) and also to bind to human serum albumin (HSA) to give an increased plasma half-life and potentially enhanced tumor penetration.
Interventions
- COMBINATION_PRODUCT MP0250 DARPin® drug candidate, Osimertinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-03-22 |
| Est. Completion | 2020-04-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03418532
The ClinicalTrials.gov registry entry for NCT03418532 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Molecular Partners, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MP0250 DARPin® drug candidate, Osimertinib is the first listed.
NCT03418532 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03418532 about?
NCT03418532 is a clinical study titled "MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC". The purpose of this study is to assess the anti-tumor efficacy, safety, tolerability, pharmacokinetics (PK), immunogenicity and biological activity of the MP0250 DARPin® drug candidate in combination with osimertinib orally once daily (o.d.), when administered to patients with EGFR mutated, advanced...
What is the current status of trial NCT03418532?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2018-03-22. Estimated completion is 2020-04-24.
What interventions are being tested in trial NCT03418532?
The interventions under investigation include: MP0250 DARPin® drug candidate, Osimertinib (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03418532?
This trial is sponsored by Molecular Partners, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.